Cancer angiogenesis: Targeting the heel of Achilles

Journal of Drug Targeting

Volumn 16, Issue 6, 2008, Pages 449-454

  Dass, Crispin R ^a   Choong, Peter F M ^a,b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

Angiogenesis; Drug delivery; Malignancy; Therapy; Tumour; Vasculature

Indexed keywords

ANGIOGENESIS INHIBITOR; ANGIOSTATIN; BEVACIZUMAB; CANCER GROWTH FACTOR; DEXTRAN; DOXORUBICIN; ENDOSTATIN; GLYCOSAMINOGLYCAN; LIPOSOME; PACLITAXEL; PIGMENT EPITHELIUM DERIVED FACTOR; RECEPTOR ANTIBODY; THALIDOMIDE; TISSUE INHIBITOR OF METALLOPROTEINASE; TOPOTECAN; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2 ANTIBODY; VASOACTIVE AGENT;

ANTIANGIOGENIC ACTIVITY; APOPTOSIS; ARTICLE; BLOOD VESSEL PERMEABILITY; CANCER IMMUNOTHERAPY; CANCER STAGING; CARCINOGENESIS; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; DRUG APPROVAL; DRUG DELIVERY SYSTEM; DRUG EXTRAVASATION; DRUG SENSITIVITY; DRUG TARGETING; ENCAPSULATION; GENE OVEREXPRESSION; HUMAN; LOW DRUG DOSE; LUNG NON SMALL CELL CANCER; MICROVASCULATURE; MONOTHERAPY; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECURRENT CANCER; TUMOR; TUMOR BLOOD FLOW; TUMOR GROWTH; TUMOR REGRESSION; TUMOR VASCULARIZATION;

ANGIOGENESIS INHIBITORS; DRUG DELIVERY SYSTEMS; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 47649106221     PISSN: 1061186X     EISSN: 10292330     Source Type: Journal    
DOI: 10.1080/10611860802088523     Document Type: Article

References (74)

1. Ansiaux, R., Baudelet, C., Jordan, BF, Beghein, N., Sonveaux, P., De Wever, J., Martinive, P., Gregoire, V., Feron, O. and Gallez, B. (2005) Thalidomide radiosensitizes tumors through early changes in the tumor microenvironment. Clin Cancer Res, 11:2, pp. 743-750.
2. Anwer, K., Bailey, A. and Sullivan, SM (2000) Targeted gene delivery: A two-pronged approach. Crit Rev Ther Drug Carrier Syst, 17, pp. 377-424.
3. Anwer, K., Meaney, C., Kao, G., Hussain, N., Shelvin, R., Earls, RM, Leonard, P., Quezada, A., Rolland, AP and Sullivan, SM (2000) Cationic lipid-based delivery system for systemic cancer gene therapy. Cancer Gene Ther, 7, pp. 1156-1164.
4. Batchelor, TT, Sorensen, AG, di Tomaso, E, Zhang, WT, Duda, DG, Cohen, KS, Kozak, KR, Cahill, DP, Chen, PJ, Zhu, M., Ancukiewicz, M., Mrugala, MM, Plotkin, S., Drappatz, J., Louis, DN, Ivy, P., Scadden, DT, Benner, T., Loeffler, JS, Wen, PY and Jain, RK (2007) AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell, 11:1, pp. 83-95.
5. Beckenlehner, K., Bannke, S., Spruss, T., Bernhardt, G., Schonenberg, H. and Schiess, W. (1992) Hyaluronidase enhances the activity of adriamycin in breast cancer models in vitro and in vivo. J Cancer Res Clin Oncol, 118, pp. 591-596.
6. Benjamin, LE and Keshet, E. (1997) Conditional switching of vascular endothelial growth factor (VEGF) expression in tumors: Induction of endothelial cell shedding and regression of hemangioblastoma-like vessels by VEGF withdrawal. Proc Natl Acad Sci U S A, 94, pp. 8761-8766.
7. Brock, TA, Dvorak, HF and Senger, DR (1991) Tumor-secreted vascular permeability factor increases cytosolic Ca2+ and von Willebrand factor release in human endothelial cells. Am J Pathol, 138, pp. 213-221.
8. Burton, MA, Gray, BN and Coletti, A. (1988) Effect of angiotensin II on blood flow in the transplanted sheep squamous cell carcinoma. Eur J Cancer Clin Oncol, 24, pp. 1373-1376.
9. Cady, FM, Kneuper-Hall, R. and Metcalf, JS (2006) Histologic patterns of polyethylene glycol-liposomal doxorubicin-related cutaneous eruptions. Am J Dermatopathol, 28:2, pp. 168-172.
10. Campbell, RB, Fukumura, D., Brown, EB, Mazzola, LM, Izumi, Y., Jain, RK, Torchilin, VP and Munn, LL (2002) Cationic charge determines the distribution of liposomes between the vascular and extravascular compartments of tumors. Cancer Res, 62, pp. 6831-6836.
11. Chen, Q-R, Kumar, D., Stass, SA and Mixson, AJ (1999) Liposomes complexed to plasmids encoding angiostatin and endostatin inhibit breast cancer in nude mice. Cancer Res, 59, pp. 3308-3312.
12. Cheung, AM, Brown, AS, Cucevic, V., Roy, M., Needles, A., Yang, V., Hicklin, DJ, Kerbel, RS and Foster, FS (2007) Detecting vascular changes in tumour xenografts using micro-ultrasound and micro-CT following treatment with VEGFR-2 blocking antibodies. Ultrasound Med Biol, 33:8, pp. 1259-1268.
13. Dass, CR and Burton, MA (2002) A model for evaluating selective delivery of plasmid DNA to tumours via the vasculature. Cancer Biother Radiopharm, 17, pp. 501-505.
14. Dass, CR and Burton, MA (2003) Modified microplex vector enhances transfection of cells in culture while maintaining tumour-selective gene delivery in vivo. J Pharm Pharmacol, 55, pp. 19-25.
15. Dass, CR, Walker, TL, Kalle, WH and Burton, MA (2000) A microsphere-liposome (microplex) vector for targeted gene therapy of cancer. II. In vivo biodistribution study in a solid tumor model. Drug Deliv, 7:1, pp. 15-19.
16. Dass, CR, Walker, TL and Burton, MA (2002) Liposomes containing cationic dimethyl dioctadecyl ammonium bromide (DDAB): Formulation, quality control and lipofection efficiency. Drug Deliv, 9, pp. 11-18.
17. Dass, CR, Tran, TMN and Choong, PFM (2007) Angiogenesis inhibitors and the need for anti-angiogenic therapeutics. J Dent Res, 86, pp. 927-936.
18. Dass, CR, Contreras, KG, Dunstan, DE and Choong, PF (2007) Chitosan microparticles encapsulating PEDF plasmid demonstrate efficacy in an orthotopic metastatic model of osteosarcoma. Biomaterials, 28, pp. 3026-3033.
19. Dawson, DW, Volpert, OV, Gillis, P., Crawford, SE, Xu, H., Benedict, W. and Bouck, NP (1999) Pigment epithelium-derived factor: A potent inhibitor of angiogenesis. Science, 285:5425, pp. 245-248.
20. Dellian, M., Yuan, F., Trubetskoy, VS, Torchilin, VP and Jain, RK (2000) Vascular permeability in a human tumour xenograft: Molecular charge dependence. Br J Cancer, 82, pp. 1513-1518.
21. Dickson, PV, Hamner, JB, Sims, TL, Fraga, CH, Ng, CY, Rajasekeran, S., Hagedorn, NL, McCarville, MB, Stewart, CF and Davidoff, AM (2007) Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy. Clin Cancer Res, 13:13, pp. 3942-3950.
22. Dings, RP, Loren, M., Heun, H., McNiel, E., Griffioen, AW, Mayo, KH and Griffin, RJ (2007) Scheduling of radiation with angiogenesis inhibitors anginex and Avastin improves therapeutic outcome via vessel normalization. Clin Cancer Res, 13:11, pp. 3395-3402.
23. Dong, Z., Zeitlin, BD, Song, W., Sun, Q., Karl, E., Spencer, DM, Jain, HV, Jackson, T., Nunez, G. and Nor, JE (2007) Level of endothelial cell apoptosis required for a significant decrease in microvessel density. Exp Cell Res, 313, pp. 3645-3657.
24. Eichhorn, ME, Becker, S., Strieth, S., Werner, A., Sauer, B., Teifel, M., Ruhstorfer, H., Michaelis, U., Griebel, J., Brix, G., Jauch, KW and Dellian, M. (2006) Paclitaxel encapsulated in cationic lipid complexes (MBT-0206) impairs functional tumor vascular properties as detected by dynamic contrast enhanced magnetic resonance imaging. Cancer Biol Ther, 5:1, pp. 89-96.
25. Eichhorn, ME, Luedemann, S., Strieth, S., Papyan, A., Ruhstorfer, H., Haas, H., Michaelis, U., Sauer, B., Teifel, M., Enders, G., Brix, G., Jauch, KW, Bruns, CJ and Dellian, M. (2007) Cationic lipid complexed camptothecin (EndoTAG((R))-2) improves antitumoral efficacy by tumor vascular targeting. Cancer Biol Ther, 6:6, pp. 920-929.
26. Ek, ET, Dass, CR, Contreras, KG and Choong, PF (2007) Inhibition of orthotopic osteosarcoma growth and metastasis by multitargeted antitumor activities of pigment epithelium-derived factor. Clin Exp Mets, 24, pp. 93-106.
27. Ek, ET, Dass, CR, Contreras, KG and Choong, PF (2007) Pigment epithelium-derived factor overexpression inhibits orthotopic osteosarcoma growth, angiogenesis and metastasis. Cancer Gene Ther, 14, pp. 616-626.
28. Ferrara, N., Hillan, KJ, Gerber, HP and Novotny, W. (2004) Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov, 3, pp. 391-400.
29. Folkman, J. (1971) Tumor angiogenesis: Therapeutic implications. N Engl J Med, 285, pp. 1182-1186.
30. Folkman, J. and Cotran, R. (1976) Relation of vascular proliferation to tumor growth. Int Rev Exp Pathol, 16, pp. 207-248.
31. Folkman, J. and Klagsbrun, M. (1987) Angiogenic factors. Science, 235, pp. 442-447.
32. Fukumura, D., Yuan, F., Endo, M. and Jain, RK (1997) Role of nitric oxide in tumor microcirculation. Blood flow, vascular permeability and leukocyte-endothelial interactions. Am J Pathol, 150, pp. 713-725.
33. Ganss, R. (2006) Tumor stroma fosters neovascularization by recruitment of progenitor cells into the tumor bed. J Cell Mol Med, 10:4, pp. 857-865.
34. Handsley, MM and Edwards, DR (2005) Metalloproteinases and their inhibitors in tumor angiogenesis. Int J Cancer, 115:6, pp. 849-860.
35. Hashizume, H., Baluk, P., Morikawa, S., McLean, JW, Thurston, G., Roberge, S., Jain, RK and McDonald, DM (2000) Openings between defective endothelial cells explain tumor vessel leakiness. Am J Pathol, 156, pp. 1363-1380.
36. Hobarth, K., Maier, U. and Marberger, M. (1992) Topical chemoprophylaxis of superficial bladder cancer with mitomycin C and adjuvant hyaluronidase. Eur Urol, 21, pp. 206-210.
37. Hobbs, SK, Monsky, WL, Yuan, F., Roberts, WG, Griffith, L., Torchilin, VP and Jain, RK (1998) Regulation of transport pathways in tumor vessels: Role of tumor type and microenvironment. Proc Natl Acad Sci U S A, 95, pp. 4607-4612.
38. Jain, RK (2001) Delivery of molecular and cellular medicine to solid tumors. Adv Drug Deliv Rev, 46, pp. 149-168.
39. Jakowlew, SB (2006) Transforming growth factor-beta in cancer and metastasis. Cancer Metastasis Rev, 25:3, pp. 435-457.
40. Johnston, SR and Gore, ME (2001) Caelyx: Phase II studies in ovarian cancer. Eur J Cancer, 37, p. S8.
41. Juliano, RL (1993) The role of β1 integrins in tumors. Semin Cancer Biol, 4, pp. 277-283.
42. Kamat, AA, Kim, TJ, Landen Jr., CN, Lu, C., Han, LY, Lin, YG, Merritt, WM, Thaker, PH, Gershenson, DM, Bischoff, FZ, Heymach, JV, Jaffe, RB, Coleman, RL and Sood, AK (2007) Metronomic chemotherapy enhances the efficacy of antivascular therapy in ovarian cancer. Cancer Res, 67:1, pp. 281-288.
43. Klimuk, SK, Semple, SC, Nahirney, PN, Mullen, MC, Bennett, CF, Scherrer, P. and Hope, MJ (2000) Enhanced anti-inflammatory activity of a liposomal intercellular adhesion molecule-1 antisense oligodeoxynucleotide in an acute model of contact hypersensitivity. J Pharmacol Exp Ther, 292, pp. 480-488.
44. Kong, G., Braun, RD and Dewhirst, MW (2000) Hyperthermia enables tumor-specific nanoparticle delivery: Effect of particle size. Cancer Res, 60, pp. 4440-4445.
45. Kong, G., Braun, RD and Dewhirst, MW (2001) Characterization of the effect of hyperthermia on nanoparticle extravasation from tumor vasculature. Cancer Res, 61, pp. 3027-3032.
46. Koukourakis, MI, Koukouraki, S., Fezoulidis, I., Kelekis, N., Kyrias, G., Archimandritis, S. and Karkavitsas, N. (2000) High intratumoural accumulation of stealth liposomal doxorubicin (Caelyx) in glioblastomas and in metastatic brain tumours. Br J Cancer, 83, pp. 1281-1286.
47. Kristensen, CA, Roberge, S. and Jain, RK (1997) Effect of tumor necrosis factor alpha on vascular resistance, nitric oxide production and glucose and oxygen consumption in perfused tissue-isolated human melanoma xenografts. Clin Cancer Res, 3, pp. 319-324.
48. Kunstfeld, R., Wickenhauser, G., Michaelis, U., Teifel, M., Umek, W., Naujoks, K., Wolff, K. and Petzelbauer, P. (2003) Paclitaxel encapsulated in cationic liposomes diminishes tumor angiogenesis and melanoma growth in a "humanized" SCID mouse model. J Invest Dermatol, 120, pp. 476-482.
49. Leonetti, C., Biroccio, A., Benassi, B., Stringaro, A., Stoppacciaro, A., Semple, SC and Zupi, G. (2001) Encapsulation of c-myc antisense oligodeoxynucleotides in lipid particles improves antitumoral efficacy in vivo in a human melanoma line. Cancer Gene Ther, 8, pp. 459-468.
50. Liu, F., Qi, H., Huang, L. and Liu, D. (1997) Factors controlling the efficiency of cationic lipid-mediated transfection in vivo via intravenous administration. Gene Ther, 4, pp. 517-523.
51. Lu, J., Jackson, JK, Gleave, ME and Burt, HM (2007) The preparation and characterization of anti-VEGFR2 conjugated, paclitaxel-loaded PLLA or PLGA microspheres for the systemic targeting of human prostate tumors. Cancer Chemother Pharmacol
52. Mancuso, MR, Davis, R., Norberg, SM, O'Brien, S., Sennino, B., Nakahara, T., Yao, VJ, Inai, T., Brooks, P., Freimark, B., Shalinsky, DR, Hu-Lowe, DD and McDonald, DM (2006) Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J Clin Invest, 116:10, pp. 2610-2621.
53. Michel, CC (1988) Capillary permeability and how it may change. J Physiol, 404, pp. 1-29.
54. Miller, DW, Vosseler, S., Mirancea, N., Hicklin, DJ, Bohlen, P., Volcker, HE, Holz, FG and Fusenig, NE (2005) Rapid vessel regression, protease inhibition, and stromal normalization upon short-term vascular endothelial growth factor receptor 2 inhibition in skin carcinoma heterotransplants. Am J Pathol, 167:5, pp. 1389-1403.
55. Mui, B., Raney, SG, Semple, SC and Hope, MJ (2001) Immune stimulation by a CpG-containing oligodeoxynucleotide in enhanced when encapsulated and delivered in lipid particles. J Pharmacol Exp Ther, 298, pp. 1185-1192.
56. Mukhopadhyay, D., Nagy, JA, Manseau, EJ and Dvorak, HF (1998) Vascular permeability factor/vascular endothelial derived growth factor mediated signaling in mouse mesentary vascular endothelium. Cancer Res, 58, pp. 1278-1284.
57. Nakahara, T., Norberg, SM, Shalinsky, DR, Hu-Lowe, DD and McDonald, DM (2006) Effect of inhibition of vascular endothelial growth factor signaling on distribution of extravasated antibodies in tumors. Cancer Res, 66:3, pp. 1434-1445.
58. Netti, PA, Berk, DA, Swartz, MA, Grodzinsky, AJ and Jain, RK (2000) Role of extracellular matrix assembly in interstitial transport in solid tumors. Cancer Res, 60, pp. 2497-2503.
59. Nishi, T., Yoshizato, K., Yamashiro, S., Takeshima, H., Sato, K., Hamada, K., Kitamura, I., Yoshimura, T., Saya, H., Kuratsu, J. and Ushio, Y. (1996) High-efficiency in vivo gene transfer using intraarterial plasmid DNA injection following in vivo electroporation. Cancer Res, 56, pp. 1050-1055.
60. Patan, S., Munn, LL and Jain, RK (1996) Intussusceptive microvascular growth in a human colon adenocarcinoma xenograft: A novel mechanism of tumor angiogenesis. Microvasc Res, 51, pp. 260-272.
61. Rainov, NG, Ikeda, K., Qureshi, NH, Grover, S., Herrlinger, U., Pechan, P., Chiocca, EA, Breakefield, XO and Barnett, FH (1999) Intraarterial delivery of adenovirus vectors and liposome-DNA complexes to experimental brain neoplasms. Hum Gene Ther, 10, pp. 311-318.
62. Ruoslahti, E. and Reed, JC (1994) Anchorage dependence, integrins and apoptosis. Cell, 77, pp. 477-478.
63. Sangai, T., Ishii, G., Kodama, K., Miyamoto, S., Aoyagi, Y., Ito, T., Magae, J., Sasaki, H., Nagashima, T., Miyazaki, M. and Ochiai, A. (2005) Effect of differences in cancer cells and tumor growth sites on recruiting bone marrow-derived endothelial cells and myofibroblasts in cancer-induced stroma. Int J Cancer, 115:6, pp. 885-892.
64. Schmid, RM, Weidenbach, H., Yamagushi, H., Luhrs, H., Liptay, S. and Adler, G. (1998) Direct gene transfer into the rat pancreas using DNA-liposomes. Eur J Clin Invest, 28, pp. 220-226.
65. Sevick, EM and Jain, RK (1991) Effect of red blood cell rigidity on tumor blood flow: Increase in viscous resistance during hyperglycemia. Cancer Res, 51, pp. 2727-2730.
66. Stearne, LE, Schifferlers, RM, Smouter, E., Bakker-Woudenberg, IA and Gussens, IC (2002) Biodistribution of long-circulating PEG-liposomes in a murine model of established subcutaneous abscesses. Biochim Biophys Acta, 1561, pp. 91-97.
67. Tabruyn, SP and Griffioen, AW (2007) Molecular pathways of angiogenesis inhibition. Biochem Biophys Res Commun, 355:1, pp. 1-5.
68. Thurston, G., McLean, JW, Rizen, M., Baluk, P., Haskell, A., Murphy, TJ, Hanahan, D. and McDonald, DM (1998) Cationic liposomes target angiogenic endothelial cells in tumors and chronic inflammation in mice. J Clin Invest, 101, pp. 1401-1413.
69. Tong, RT, Boucher, Y., Kozin, SV, Winkler, F., Hicklin, DJ and Jain, RK (2004) Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res, 64:11, pp. 3731-3736.
70. Tsafnat, N., Tsafnat, G., Lambert, TD and Jones, SK (2005) Modelling heating of liver tumours with heterogeneous magnetic microsphere deposition. Phys Med Biol, 50:12, pp. 2937-2953.
71. Vosseler, S., Mirancea, N., Bohlen, P., Mueller, MM and Fusenig, NE (2005) Angiogenesis inhibition by vascular endothelial growth factor receptor-2 blockade reduces stromal matrix metalloproteinase expression, normalizes stromal tissue, and reverts epithelial tumor phenotype in surface heterotransplants. Cancer Res, 65:4, pp. 1294-1305.
72. Weinbaum, S., Cowin, SC and Zeng, Y. (1994) A model for the excitation of osteocytes by mechanical loading-induced bone fluid shear stresses. J Biomech, 27, pp. 339-360.
73. Yasui, N., Mori, T., Morito, D., Matsushita, O., Kourai, H., Nagata, K. and Koide, T. (2003) Dual-site recognition of different extracellular matrix components by anti-angiogenic/neurotrophic serpin, PEDF. Biochemistry, 42:11, pp. 3160-3167.
74. Yoshida, S., Ono, M., Shono, T., Izumi, H., Ishibashi, T., Suzuki, H. and Kuwano, M. (1997) Involvement of interleukin-8, vascular endothelial growth factor, and basic fibroblast growth factor in tumor necrosis factor alpha-dependent angiogenesis. Mol Cell Biol, 17:7, pp. 4015-4023.